Climate Change Data

Abera Bioscience AB

Climate Impact & Sustainability Data (2020)

Reporting Period: 2020

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Strengthened and broadened the competence in the board by electing Cristina Glad and Fredrik Juserius.
  • Launched an employee and board option program to motivate and secure long-term commitment.

Governance Achievements

  • Strengthened and broadened the competence in the board by electing Cristina Glad and Fredrik Juserius.
  • Launched an employee and board option program to motivate and secure long-term commitment.

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Initiate clinical phase 1 with Ab-01.12 during the second half of 2022.
  • Begin the process for regulatory permits from authorities required for clinical studies with Ab-01.12 during H1 2021.

Environmental Challenges

  • Dependence on collaboration partners
  • Financing needs and capital
  • Key personnel and employees
  • Registration and permits from authorities
  • Clinical studies
  • Development costs
  • COVID-19
  • Patents and intellectual property rights
Mitigation Strategies
  • The company plans to initiate collaborations with several partners, both for the development and commercialization of vaccines, and to access expertise and resources for specific parts of different development phases, e.g., contract research, GMP production, and regulatory expertise.
  • The company has a assessed capital requirement before clinical studies can be initiated with the company's main product. Future market breakthroughs may be delayed, which may lead to further capital requirements.
  • The company's key personnel have extensive expertise and experience in the company's field of operations.
  • Abera is dependent on ethical permits from the Medical Products Agency in each country to conduct studies in humans.
  • The pharmaceutical industry in general and clinical studies in particular are associated with great uncertainty and risks regarding delays and results in the studies.
  • Abera will continue to develop and further develop products within its field of operations.
  • The company has been affected and will continue to be affected by the current pandemic in various parts of the business, which means that there is a risk of negative financial impact.
  • The company has approved patents and has applied for patents in several countries regarding its platform technology.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed